ArticleCureus2026
Acute Kidney Injury (AKI) in Severe Plasmodium falciparum Malaria Among Adult Sudanese Patients in Kosti Teaching Hospital, 2025.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Acute kidney injury (AKI) is a frequent and serious complication of severe malaria (SM), contributing significantly to morbidity and mortality. In endemic regions like Sudan, AKI complicates the clinical course of SM, yet detailed demographic, clinical, and outcome data remain limited. Aim This study aimed to characterize the demographic profile, clinical features, management strategies, and outcomes of AKI in patients with SM in Sudan. Methods A cross-sectional analysis of 100 SM patients with AKI was conducted in Kosti Teaching Hospital from February to May 2025. Data on demographics, comorbidities, malaria complications, AKI severity (classified via Kidney Disease: Improving Global Outcomes (KDIGO) criteria), treatment regimens, contributing factors, interventions, and outcomes were collected from medical records. The statistical analysis was performed using SPSS (IBM SPSS Statistics for Windows, IBM Corp., Version 26.0, Armonk, NY). Results Patients were predominantly male (64 (64%)) with a mean age of 48 years (SD 22); 43 (43%) were under 40 years of age. Central Sudan residents comprised 67 (67%) of cases. Hyperparasitemia (92 (92%)), circulatory shock (58 (58%)), and prostration (44 (44%)) were frequent complications. Hypertension (36 (36%)) and diabetes (20 (20%)) were leading comorbidities. Artesunate was the primary treatment (68 (68%)). AKI severity included Stage 1 (44 (44%)), Stage 2 (28 (28%)), and Stage 3 (28 (28%)). Hypovolemia (95 (95%)) and sepsis (63 (63%)) were key contributors. Interventions included IV fluids (94 (94%)) and antibiotics (74 (74%)). Outcomes revealed full renal recovery in 55 (55%), partial recovery in 28 (28%), progression to chronic kidney disease in 13 (13%), and a four (4%) mortality rate. Conclusion SM-associated AKI in Sudan predominantly affects younger people as well as males and is frequently linked to hyperparasitemia, circulatory shock, and comorbid hypertension. Despite high rates of severe AKI, over half of patients achieve full renal recovery with appropriate treatment, though a notable proportion progress to chronic kidney disease or die.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.